Physician profile
Eric Stuart
NPI 1447244819
$409.95
in general payments reported to CMS, 2019-2025
12 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.10 · 2022: $50.20 · 2023: $116 · 2024: $119 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.65 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $116.00 | 2023 | Ozempic |
| Argenx US, INC. | $52.02 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $42.41 | 2024 | |
| Abbvie INC. | $34.23 | 2024 | |
| Pfizer INC. | $31.68 | 2025 | |
| Neurelis, INC. | $25.65 | 2024 | Valtoco |
| Livanova USA, INC. | $23.10 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.04 | 2022 | |
| Amgen INC. | $17.57 | 2025 | Repatha |
| Esperion Therapeutics, INC. | $17.09 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $14.66 | 2022 | |
| Medtronic, INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.